Abstract
Growth factor receptor-mediated signal transduction has been implicated in conferring resistance to conventional chemotherapy on cancer cells. In this study, we delineated a pathway that involves HER2/PI-3K/Akt in mediating multidrug resistance in human breast cancer cells. We found that the cell lines that express both HER2 and HER3 appear to have a higher phosphorylation level of Akt (activated Akt). Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin). Selective inhibition of PI-3K or Akt activity with their respective dominant-negative expression vectors sensitized the cells to the induction of apoptosis by the chemotherapeutic agents. We further demonstrated that MCF7 cells expressing a constitutively active Akt, in which the phospholipid-interactive PH domain of Akt was replaced by a farnesylation sequence for constitutive membrane anchorage (ΔPH-Akt1-farn), showed a similar increased resistance to the chemotherapeutic agents. Our results suggest that activation of Akt1 by HER2/PI-3K plays an important role in conferring a broad-spectrum chemoresistance on breast cancer cells and that Akt may therefore be a novel molecular target for therapies that would improve the outcome of patients with breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- ΔPH-Akt1-farn:
-
Flag-tagged farnesylation Akt1 lacking the PH domain
- PI:
-
phosphatidylinositol
- PI(3,4,5) P3:
-
PI 3,4,5-triphosphate
- PI-3K:
-
phosphoinoside-3 kinase
- FBS:
-
fetal bovine serum
References
Alessi DR and Cohen P . (1998). Curr. Opin. Genet. Dev., 8, 55–62.
Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Panici PB, Mancuso S, Neri G and Testa JR . (1995). Int. J. Cancer, 64, 280–285.
Bellacosa A, Testa JR, Staal SP and Tsichlis PN . (1991). Science, 254, 274–277.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden K.C, Blenis J and Greenberg ME . (1999). Cell, 96, 857–868.
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC . (1998). Science, 282, 1318–1321.
Cheng JQ, Altomare DA, Klein MA, Lee WC, Kruh GD, Lissy NA and Testa JR . (1997). Oncogene, 14, 2793–2801.
Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK and Testa JR . (1996). Proc. Natl. Acad. Sci. USA, 93, 3636–3641.
Datta K, Bellacosa A, Chan TO and Tsichlis PN . (1996). J. Biol. Chem., 271, 30835–30839.
del Peso L, Gonzalez-Garcia M, Page C, Herrera R and Nunez G . (1997). Science, 278, 687–689.
Fan Z, Lu Y, Wu X, DeBlasio A, Koff A and Mendelsohn J . (1995). J. Cell Biol., 131, 235–242.
Hermanto U, Zong CS and Wang LH . (2001). Oncogene, 20, 7551–7562.
Liu AX, Testa JR, Hamilton TC, Jove R, Nicosia SV and Cheng JQ . (1998). Cancer Res., 58, 2973–2977.
Nicholson KM and Anderson NG . (2002). Cell Signal., 14, 381–395.
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Dormer DB . (1999). Nature, 401, 82–85.
Perez-Tenorio G and Stal O . (2002). Br. J. Cancer, 86, 540–545.
Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM and Sellers WR . (1999). Proc. Natl. Acad. Sci. USA, 96, 2110–2115.
Romashkova JA and Makarov SS . (1999). Nature, 401, 86–90.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL . (1987). Science, 235, 177–182.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A . (1989). Science, 244, 707–712.
Stambolic V, Suzuki A, de laPompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP and Mak TW . (1998). Cell, 95, 29–39.
Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV and Cheng JQ . (2001). Cancer Res., 61, 5985–5991.
Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Bookstein R, Bolen JB and Steck PA . (1997). Cancer Res., 57, 5221–5225.
Testa JR and Bellacosa A . (2001). Proc. Natl. Acad. Sci. USA, 98, 10983–10985.
Yu D and Hung MC . (2000). Oncogene, 19, 6115–6121.
Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV and Cheng JQ . (2000). Oncogene, 19, 2324–2330.
Acknowledgements
We are grateful to Michael Worley of the Department of Scientific Publications for editorial assistance with the manuscript. This work was supported in part by the US Army Department of Defense Medical Research Grant DAMD 17-00-1-0461, a grant from The Breast Cancer Research Foundation (New York), the NCI RO1 Grant CA82716, and Cancer Center core Grant CA16672.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Knuefermann, C., Lu, Y., Liu, B. et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22, 3205–3212 (2003). https://doi.org/10.1038/sj.onc.1206394
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206394
Keywords
This article is cited by
-
HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
Cancer Cell International (2023)
-
HER3 in cancer: from the bench to the bedside
Journal of Experimental & Clinical Cancer Research (2022)
-
Direct knockdown of phospho-PTM targets mediated by TRIM21 can improve personalized treatment in breast cancer
Cellular Oncology (2022)
-
The expression of miRNA-152-3p and miRNA-185 in tumor tissues versus margin tissues of patients with chemo-treated breast cancer
BMC Research Notes (2021)
-
LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway
Cancer Cell International (2019)